("Profusa” or the "Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation ...
The ASH oral presentation today reports data from the ongoing dose escalation and dose expansion parts of the CARDINAL study of TERN-701 in patients with previously treated CML. As of the September 13 ...
BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS®) Phase 3 study ...
Lyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, ...
Detailed price information for Briacell Therapeutics Corp (BCT-T) from The Globe and Mail including charting and trades.
Investors and analysts are invited to register to attend in person by emailing Nick Smith, Head of Investor Relations ( [email protected] ). A webcast will be available via the events page of the ...
ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting ...
AMD Phase 3 timing, Otsuka funding to 2028, and mixed 4D-710 data with financial risk. See why FDMT stock is a hold.
Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.
Kyverna Therapeutics, Inc. shares surged on strong Phase 2 KYSA-8 data for Miv-cel in stiff person syndrome. Read why KYTX ...
Menin inhibitors target the interaction between menin and the KMT2A complex, offering a breakthrough in treating acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback